Insmed Incorporated

Insmed Incorporated company information, Employees & Contact Information

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. We are dedicated to making a meaningful impact in patients’ lives as well as the communities where we live and work. Our team is guided by our core values of collaboration, accountability, passion, respect, and integrity. Insmed is headquartered in Bridgewater, NJ, and has offices and research locations throughout the United States, Europe, and Japan. We are proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Join the Insmed team to accelerate your career and help make every moment and every patient count. Community guidelines: http://bit.ly/3DbEjVG

Company Details

Employees
1.47K
Address
700 Us 206, Bridgewater Township,new Jersey 08807,united States
Phone
(732) 997-4600
Email
bu****@****med.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
insmed.com
HQ
Bridgewater Township, New Jersey
Looking for a particular Insmed Incorporated employee's phone or email?

Insmed Incorporated Questions

News

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List - PR Newswire

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List PR Newswire

Insmed (Nasdaq: INSM) named No. 1 biopharma employer by Science for fifth straight year - Stock Titan

Insmed (Nasdaq: INSM) named No. 1 biopharma employer by Science for fifth straight year Stock Titan

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 - Yahoo Finance

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 Yahoo Finance

Insmed Announces Proposed $650 Million Public Offering of Common Stock - Insmed Incorporated Investor Relations

Insmed Announces Proposed $650 Million Public Offering of Common Stock Insmed Incorporated Investor Relations

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 - Yahoo Finance

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 Yahoo Finance

Q3 2025 Results on Oct. 30 — Insmed Schedules Investor Call; Live Webcast & Replay - Stock Titan

Q3 2025 Results on Oct. 30 — Insmed Schedules Investor Call; Live Webcast & Replay Stock Titan

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update PR Newswire

Insmed To Present at September Investor Conferences - Yahoo Finance

Insmed To Present at September Investor Conferences Yahoo Finance

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Yahoo Finance

115 New Hires Receive $9.6M+ in Stock Awards: Insmed's Major Talent Investment Under NASDAQ Rules - Stock Titan

115 New Hires Receive $9.6M+ in Stock Awards: Insmed's Major Talent Investment Under NASDAQ Rules Stock Titan

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 - PR Newswire

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 PR Newswire

Biotech Leader Insmed Announces Double-Header: Wells Fargo and Morgan Stanley Healthcare Conferences - Stock Titan

Biotech Leader Insmed Announces Double-Header: Wells Fargo and Morgan Stanley Healthcare Conferences Stock Titan

Insmed Sets Q2 2025 Earnings Date: Biopharma Leader to Discuss Financial Results August 7 - Stock Titan

Insmed Sets Q2 2025 Earnings Date: Biopharma Leader to Discuss Financial Results August 7 Stock Titan

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension - Yahoo Finance

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension Yahoo Finance

Insmed CEO Takes Stage at Goldman Sachs Healthcare Conference: Key Updates Expected - Stock Titan

Insmed CEO Takes Stage at Goldman Sachs Healthcare Conference: Key Updates Expected Stock Titan

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis - PR Newswire

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis PR Newswire

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis - PR Newswire

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis PR Newswire

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 - PR Newswire

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 PR Newswire

FDA Makes History: First-Ever Treatment for 500,000 Non-Cystic Fibrosis Bronchiectasis Patients Gets Approval - Stock Titan

FDA Makes History: First-Ever Treatment for 500,000 Non-Cystic Fibrosis Bronchiectasis Patients Gets Approval Stock Titan

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Insmed Incorporated Investor Relations

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference Insmed Incorporated Investor Relations

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good - PR Newswire

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good PR Newswire

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List - Yahoo Finance

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List Yahoo Finance

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update PR Newswire

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 - PR Newswire

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 PR Newswire

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health - PR Newswire

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health PR Newswire

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI - PR Newswire

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI PR Newswire

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More" - PR Newswire

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More" PR Newswire

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC - PR Newswire

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC PR Newswire

Insmed Announces Strategic Financings Totaling $775 Million - PR Newswire

Insmed Announces Strategic Financings Totaling $775 Million PR Newswire

Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference - Insmed Incorporated Investor Relations

Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference Insmed Incorporated Investor Relations

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP) - PR Newswire

Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP) PR Newswire

Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 - PR Newswire

Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028 PR Newswire

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) - PR Newswire

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) PR Newswire

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference The Malaysian Reserve

Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor - Insmed Incorporated Investor Relations

Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor Insmed Incorporated Investor Relations

Top Insmed Incorporated Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant